Promoting smart wearable devices in the health-AI market: the role of health consciousness and privacy protection: An International Journal

PurposeConsumers interacting with smart wearable devices is on the rise in the current health-AI market, which offers a great opportunity for companies to execute interactive marketing. However, this opportunity is mainly reliant on consumers' use of smart wearable devices. This paper aims to develop a model considering health and privacy factors to elucidate consumers' use of smart wearable devices for unleashing their full potential in interactive marketing.Design/methodology/approachThe authors collected 250 samples via an online survey to validate the smart wearable devices usage model that elucidates factors that stimulate consumer usage, including privacy concerns, health consciousness and consumer innovativeness. The authors used structural equation modeling and multi-group analysis to test the hypotheses.FindingsPrivacy concerns of consumers have a negative effect on smart wearable devices usage, while health consciousness positively impacts consumers' usage of smart wearable devices. Consumer innovativeness indirectly affects smart wearable devices usage via effort expectancy. Experienced consumers are less sensitive to the performance expectancy but more affected by effort expectancy regarding smart wearable devices.Originality/valueThe present study contributes to the literature stream of health-AI usage by unraveling the impacts of privacy concerns and health consciousness and examining the moderating role of prior experience. The findings suggest marketers in the health-AI industry should endeavor to build transparent and sound privacy protection mechanisms and promote smart wearable devices by fostering health awareness of potential consumers.

Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy.

Tumor-associated adipocytes (TAAs) recruit monocytes and promote their differentiation into tumor-associated macrophages (TAMs) that support tumor development. Here, TAAs are engineered to promote the polarization of TAMs to the tumor suppressive M1 phenotype. Telratolimod, a toll-like receptor 7/8 agonist, is loaded into the lipid droplets of adipocytes to be released at the tumor site upon tumor cell-triggered lipolysis. Locally administered drug-loaded adipocytes increased tumor suppressive M1 macrophages in both primary and distant tumors and suppressed tumor growth in a melanoma model. Furthermore, drug-loaded adipocytes improved CD8+ T cell-mediated immune responses within the tumor microenvironment and favored dendritic cell maturation in the tumor draining lymph nodes.

Iron oxide nanoparticles augment the intercellular mitochondrial transfer-mediated therapy.

The transfer of mitochondria between cells has recently been revealed as a spontaneous way to protect the injured cells. However, the utilization of this natural transfer process for disease treatment is so far limited by its unsatisfactory transfer efficiency and selectivity. Here, we demonstrate that iron oxide nanoparticles (IONPs) can augment the intercellular mitochondrial transfer from human mesenchymal stem cells (hMSCs) selectively to diseased cells, owing to the enhanced formation of connexin 43­containing gap junctional channels triggered by ionized IONPs. In a mouse model of pulmonary fibrosis, the IONP-engineered hMSCs achieve a remarkable mitigation of fibrotic progression because of the promoted intercellular mitochondrial transfer, with no serious safety issues identified. The present study reports a potential method of using IONPs to enable hMSCs for efficient and safe transfer of mitochondria to diseased cells to restore mitochondrial bioenergetics.